Diabetes mellitus and dialysis

Minerva Urologica e Nefrologica

Volumn 56, Issue 3, 2004, Pages 289-303

  Stein, G ^a   Funfstuck R ^b   Schiel, R ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Sophien und Hufeland Klinikum Weimar   (Germany)

^c Inselklinik Heringsdorf ^*  (Germany)

Author keywords

Dialysis; Kidney failure, chronic; Peritoneal dialysis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIALYSIS FLUID; GLUCOSE; POTASSIUM;

AGE; ANEMIA; ARTERIOVENOUS FISTULA; ARTERY CALCIFICATION; AUTOMATION; CALORIC INTAKE; COMORBIDITY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSATE; DIALYSIS; GASTROINTESTINAL DISEASE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOVOLEMIA; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALNUTRITION; MORBIDITY; MORTALITY; PERIPHERAL VASCULAR DISEASE; PERITONEAL DIALYSIS; REVIEW; RISK ASSESSMENT; STROKE; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ACCESS;

DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PROGNOSIS; RENAL DIALYSIS; SURVIVAL RATE; TIME FACTORS;

EID: 4544261413     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. National Institutes of Health, NIDDK/DKUHD. Excerpts from the United States renal data system's. 2003 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2003;42:S1-S226.
2. Frei U, Schober-Halstenberg HJ. Nierenersatztherapie in Deutschland. Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 2002/2003. 2003; http://www.quasi-niere.org
3. Frei U, Schober-Halstenberg HJ and the QuaSi-Niere Task Group for Quality Assurance in Renal Replacement Therapy. Annual report of the German renal registry 1998. Nephrol Dial Transplant 1999;14:1085-90.
4. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 2003;18:1716-25.
5. Perez-Garcia R, Rodriguez Benitez P, Verde E, Valderrabano F. Increasing of renal replacement therapy (RRT) in diabetic patients in Madrid. Nephrol Dial Transplant 1998;13:2743-5.
6. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.
7. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14:S1-5.
8. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998;21:296-309.
9. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA et al. The rising prevalence of diabetes and impaired glucose tolerance. The Australian diabetes, obesity and lifestyle study. Diabetes Care 2002;25:829-34.
10. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987;30:123-31.
11. Lin CL, Wu MS, Hsu PY, Huang CC. Improvement of clinical outcome by early nephrology referral in type II diabetics on hemodialysis. Ren Fail 2003;25:455-64.
12. Van Biesen W, Vanholder RC, Veys N, Dhondt A, Lameire NH. An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol 2000;11:116-25.
13. Gandjour A, Lauterbach KW. An evidence-based disease-management program for patients with diabetic nephropathy. J Nephrol 2003;16:500-10.
14. Hays RD, Kalich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KD-QOL) instrument. Qual Life Res 1994;3:329-38.
15. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001;24:909-13.
16. Striker GE. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. Nephrol Dial Transplant 1995;10:290-2.
17. Snow V, Weiss KB, Mottur-Pilson C, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003;138:587-92.
18. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003;138:593-602.
19. NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation. Am J Kidney Dis 1997;30:S15-66.
20. Vanholder R, Hoenich NA, Ringoir S. Single-needle haemodialysis. In: Maher JF, editor. Replacement of renal function by dialysis. Dordrecht, The Netherlands: Kluwer; 1989.p.382-99.
21. Andreucci VE, Kerr DNS, Kopple JD. Rights of chronic renal failure patients undergoing chronic dialysis therapy. Nephrol Dial Transplant 2004;19:30-8.
22. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B et al. Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 2002;61:305-16.
23. Zhang L, Krzentowski G, Albert A, Lefèbvre PJ. Factors predictive of nephropathy in type 1 diabetic patients with good or poor metabolic control. Diabet Med 2003;20:580-5.
24. Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 2004;15:S25-9.
25. Dikow R, Ritz E. Cardiovascular complications in the diabetic patient with renal disease: An update in 2003. Nephrol Dial Transplant 2003;18:1993-8.
26. Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001;38:992-1000.
27. Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, Murray DC et al. Cardiac disease in diabetic end-stage renal disease. Diabetologia 1997;40:1307-12.
28. Foley N. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 2003;16:111-7.
29. Serkes KD, Blagg CR, Nolph KD, Vonesh EF, Shapiro F. Comparison of patients and technique survival in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis: a multicenter study. Perit Dial Int 1999;10:15-9.
30. Cano NJ, Roth H, Aparicio M, Azar R, Canaud B, Chauveau P et al. French study group for nutrition in dialysis (FSG-ND). Malnutrition in hemodialysis diabetic patients: evaluation and prognostic influence. Kidney Int 2002;62:593-601.
31. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al: Collaborative study group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
32. Akmal M. Hemodialysis in diabetic patients. Am J Kidney Dis 2001;38:S195-9.
33. Dikow R, Schwenger V, Schomig M, Ritz E. How should we manage anaemia in patients with diabetes? Nephrol Dial Transplant 2002;17:S67-72.
34. Leskinen Y, Salenius JP, Lehtimaki T, Huhtala H, Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis 2002;40:472-9.
35. Strid H, Simren M, Johansson AC, Svedlund J, Samuelsson O, Bjornsson ES. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephrol Dial Transplant 2002;17:1434-9.
36. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003;14:3270-7.
37. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
38. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-9.
39. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S et al. Intensive insulin therapy prevents the progression of diabetic microviscular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
40. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
41. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13. Erratum in: BMJ 1999;318:29.
42. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13. Erratum in: BMJ 1999;318:29.
43. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al. Life study group. Cardiovascular morbidity and mortality in the Losartan intervention for end-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
44. Neal B, MacMahon S, Chapman N; Blood pressure lowering treatment trialists' collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration Lancet 2000;356:1955-64.
45. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 individuals with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
46. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
47. McMurray SD. The challenge of diabetes care in the dialysis unit. Semin Dial 2003;16:197-8.
48. Flauto RP, Leon JB, Sehgal AR. The provision and outcomes of diabetic care of hemodialysis patients. Am J Kidney Dis 2003;41:125-31.
49. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:361-76.
50. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med 2003;20:642-5.
51. A desktop guide to type 1 (insulin-dependent) diabetes mellitus. European Diabetes Policy Group 1998. Diabet Med 1999;16:253-66.
52. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Ann Intern Med 2002;137:25-33.
53. Chiasson JL, Josse RG, Gomis R, Hanefed M, Karasik A, Laaksch M. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
54. Holman R, Cull C, Turner R for the UKPDS study group. Acarbose improves glycaemic control over three years in type 2 diabetes. Diabetes 1998;47:A93.
55. Radziuk J, Kernmer FW, Morishima T. The effect of an alpha-glucosidase hydrolase inhibitor on glycemia and the adsorption of sucrose in man determined using a tracer method. Diabetes 1984;33:207-13.
56. Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003;23:861-5.
57. Wolf G, Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 2003;14:1396-405.
58. Herbst KL, Hirsch IB. Insulin strategies for primary care providers. Clin Diab 2002;20:11-7.
59. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-33.
60. Abreira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP et al. Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Diabetes Care 1995;18:1113-23.
61. Schiel R, Müller UA. Intensive or conventional insulin therapy in type 2 diabetic patients? A population-based study on metabolic control and quality of life (The JEVIN-trial). Exp Clin Endocrinol Diabetes 1999;107:506-11.
62. Wu MS, Yu CC, Yang CW, Wu CH, Haung JY, Hong JJ et al. Poor predialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 1997;12:2105-10.
63. Shapiro FL, Comty CHM. Haemodialysis in diabetics - 1979 update. In: Friedmann EA, L'Esperance FA editors. Diabetic renal-retinal syndrome. New York, NY: Grune and Stratton; 1980.p.333-43.
64. Nakatsuka K, Hino M, Miki T. Erythropoietin treatment for anemia in endstage renal disease with diabetes mellitus. Diabetes Care 1990;13:834-5.
65. Passadakis P, Thodis E, Vargemezis V, Oreopoulos D. Long-term survival with peritoneal dialysis in ESRD due to diabetes. Clin Nephrol 2001;56:257-70.
66. Churchill DN, Thorpe KE, Teehan BP. Treatment of diabetics with endstage renal disease: lessons from the Canada-USA (CANUSA) study of peritoneal dialysis. Semin Dial 1997;10:215-8.
67. Quellhorst E. Insulin therapie during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol 2002;13(Suppl 1):93-6.
68. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Heen H. Coronary heart disease risk and impaired glucose trolerance: The White Hall Study. Lancet 1983;1:1372-6.
69. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary herat disease: result form two population studies in Finland. Diabetes Care 1973;131:141-3.
70. Schmitz O. Insulin mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes 1985;34:1152-9.
71. Johnson CA, Amidon G, Reichert JE, Porter WR. Adsorption of insulin to the surface of peritoneal dialysis solution containers. Am J Kidney Dis 1983;3:224-8.
72. Fenton SSA, Schaubel DE, Besmeules M, Morrison HI, Mao Y, Copleston P et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997;30:334-42.
73. Vonesh EF, Moran J. Mortality in end-stage renal disease: A reassessment of differendes between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1999;10:345-65.
74. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG et al. Mortality risk of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999;34:1065-74.
75. Zimmermann SW, Oxton LI, Bidwell D, Wakeen M. Long-term outcome of diabetic patients receiving peritoneal dialysis. Perit Dial Int 1996;16:63-8.
76. Kronenberg F, Mundle M, Langle M, Neyer U. Prevalence and progression of peripheral arterial calcifications in patients with ESRD. Am J Kidney Dis 2003;41:140-8.
77. McCoy KI, Goldstein DR, Gahtan V, Mayro G, Kerstein M. Peripherial vascular disease intervention in patients with end-stage renal disease: complications in those treated with peritoneal dialysis. South Med J 2001;10:1002-5.
78. Liu H, Li G. Comparison of mortality rates between peritoneal dialysis and hemodialysis in diabetic nephropathy patients. Zhonhus Nei Ke Za Zhi 2001;11:737-9.
79. Schaubel D, Fenton SSA. Trends in mortality on peritoneal dialysis: Canada 1981-1977. J Am Soc Nephrol 2000;1:126-33.
80. Serkes KD, Blagg CR, Nolph KD, Vonesh EF, Shapiro F. Comparison of patient and techniques survival in continuos ambulatory peritoneal dialysis (CAPD) and hemodialysis: a multicenter study. Perit Dial Intern 1990;10:15-9.
81. Miguel A, Garcia-Ramon R, Perez-Contreras J, Gomez-Roldan C, Alvarino J, Escobedo J et al. Levante PD multicenter group. Comorbidity and mortality in peritoneal dialysis: a comparative study of type 1 and 2 diabetes versus nondiabetic patients. Peritoneal dialysis and diabetes. Nephron 2002;90:290-6.
82. Heimbtirger O, Waniewski J, Werynski A, Tranaeus Lindholm H. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990;38:495-506.
83. Devouyst O, Topley N, Williams JD. Morphological and functional changes in the dialyzed peritoenal cavity: impact of more biocompatible solutions. Nephrol Dial Transplant 2002;17(Suppl 3):12-5.
84. De Vries AS, Tilton RG, Stephan CC, Lameire NH. Vascular endothelial growth factor is essential for hyperglycemia structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001:8:1734-41.
85. Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S et al. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 2001;16:999-1008.
86. Schwenger V, Zeier M, Henle T, Ritz E. Advanced glycation endproducts (AGE's) as uremic toxins. Nahrung 2001;3:172-6.
87. Brownlee E, Cerami A, Vlassava H. Advanced glycosilation endproducts in tissue and the biochemical basis of diabetic complication. N Engl J Med 1988;18:1315-21.
88. Mistry CD, Gokal R, Peers EM. A randomised multicenter clinical trial comparing isomolar icodextrin with hyperosmolar glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994;46:496-503.
89. Dawnay A, Millar D. Glycation and advanced end-products formation with icodextrin and dextrose. Perit Dial Int 1997;17:52-8.
90. Woodrow G, Stables G, Oldroyd B, Gisbson J, Turney JH, Braunjohn AM. Comparison of icocextrin and glucose solutions for the daytime a well in automated peritoneal dialysis. Nephrol Dial Transplan 1999;14:1530-5.
91. Riley STG, Chess J, Donovan KZ, Williams JD. Spurious hyperglycaemia and icodextrin in peritoneal dialysis. BMJ 2003;327:608-9.
92. Gokal R. Peritoneal dialysis in the 21st century. An analysis of current problems and future developments. J Am Soc Nephrol 2002;13:104-16.
93. Gokal R, Peers EM, Mobberley J, MIDAS Study Group. Effect of icodextrin use on total and LDL cholesterolemic PD patients. J Am Soc Nephrol 1998;9:283A.
94. Mackenzie RK, Holmes CJ, Moseley A, Jenkin JP, Williams JD, Coles D et al. Bicarbonate/lactate and bicarbonate buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNF alpha secretion. J Am Soc Nephrol 1998;9:1499-506.
95. Krediet RT, van Westrhenen R, Zweers MM, Struijk DG. Clinical advantages of new peritoneal dialysis solutions. Nephrol Dial Transpolant 2002;17(Suppl 3):16-8.
96. Hoff CM, Shockley TR. Peritoneal dialysis in the 21st century: The potential of gene therapy. J Am Soc Nephrol 2002;13:117-24.
97. Lindblad AS, Nolph KD, Novak JW, Friedman EA. A survey of the NIH CAPD registry population with end-stage renal disease attributed to diabetic nephropathy. J Diab Compl 1988;2:227-32.
98. Faller B, Lameire N. Evolution of clinical parameters and peritoenal function in a cohort of CAPD patients followed over 7 years. Nephrol Dial Transplant 1994;9:280-6.
99. Apostolou T, Gokal R. Neuropathy and quality of life in diabetic continuous ambulatory peritoneal dialysis patients. Perton Dial Int 1999;19:(Suppl 2):242-7.
100. Halsbeck M, Luft D, Neundörfer B, Rebaelli M, Stracke H, Ziegler D et al. Diagnose, Therapie und Verlaufskontrolle der autonomen diabetischen Neuropathie. In: Scherbaum WA, Lauterbach KW, Joost HG, editors. Evidenzbasierte Diabetes-Leitlinien. Düsseldorf: DDG; 2002.p.18-34.
101. Veves A, Websters L, Chen TF, Paynes S, Boulton AJM. Aetiopathogenesis and management of importance in diabetic males: four years experience from a combined clinic. Diabet Med 1995;12:77-82.
102. Shaw JE, Abott CA, Tindle K, Hollis S, Boulton AJM. A randomised controlle trial of tropical glycopyrolate, the first specific treatment for diabetic gustatory sweating. Diabetologia 1997;40:299-301.
103. Claus D. Diabetes und Polyneuropathie. In: Weiler C, Sliwka U, Diener HC, Wallesch CW, Busch E, editors. Neurologie. Stuttgart: Thieme; 2003.p.151-4.
104. Young MJ, Boulton AJM, Macleod AF, Williams DRF, Sonksen PM. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150-4.
105. Balaskas EV, Gupta A, Meema ME, Blair G, Bargman J. Long term continous ambulatory peritoneal dialysis in diabetics. Clin Nephrol 1994;42:54-62.
106. Viglino G, Cancarini GC, Catizone I, Cocchi R, de Vecchi A, Lupo A. Ten years experience of CAPD in diabetics: comparison of results with non diabetics. Nephrol Dial Transplant 1994;9:1443-8.
107. Nowak Z, Koniecz NAM, Wankowicz Z. Bone turn-over markers in diabetics treated with continuous ambulatory peritoneal dialysis. Pol Arch Med Wewn 1999;102:575-81.